Morgan Stanley: Shanghai Pharma's Q1 Results Align with Forecasts, Assigns "In-Line" Rating to A-Shares

Stock News05-06

Morgan Stanley has issued a research report indicating that Shanghai Pharmaceuticals (02607) reported first-quarter revenue of RMB 75.3 billion, a year-on-year increase of 6.4%, and a net profit of RMB 1.418 billion, also up 6.4% year-on-year. Both figures were in line with the firm's expectations. The report noted that Shanghai Pharmaceuticals is currently in discussions with multinational companies from the United States and the European Union regarding potential business development opportunities within its research and development pipeline. The firm has assigned an "In-line" rating to Shanghai Pharmaceuticals' (601607.SH) A-shares, with a target price of RMB 18.8.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1136361643?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-06 10:26","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1136361643","market":"sg","top_or_hot":-1,"title":"Morgan Stanley: Shanghai Pharma's Q1 Results Align with Forecasts, Assigns \"In-Line\" Rating to A-Shares","media":"Stock News","content":"<p>Morgan Stanley has issued a research report indicating that Shanghai Pharmaceuticals (02607) reported first-quarter revenue of RMB 75.3 billion, a year-on-year increase of 6.4%, and a net profit of RMB 1.418 billion, also up 6.4% year-on-year. Both figures were in line with the firm's expectations. The report noted that Shanghai Pharmaceuticals is currently in discussions with multinational companies from the United States and the European Union regarding potential business development opportunities within its research and development pipeline. The firm has assigned an \"In-line\" rating to Shanghai Pharmaceuticals' (601607.SH) A-shares, with a target price of RMB 18.8.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Morgan Stanley: Shanghai Pharma's Q1 Results Align with Forecasts, Assigns \"In-Line\" Rating to A-Shares</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMorgan Stanley: Shanghai Pharma's Q1 Results Align with Forecasts, Assigns \"In-Line\" Rating to A-Shares\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-05-06 10:26</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Morgan Stanley has issued a research report indicating that Shanghai Pharmaceuticals (02607) reported first-quarter revenue of RMB 75.3 billion, a year-on-year increase of 6.4%, and a net profit of RMB 1.418 billion, also up 6.4% year-on-year. Both figures were in line with the firm's expectations. The report noted that Shanghai Pharmaceuticals is currently in discussions with multinational companies from the United States and the European Union regarding potential business development opportunities within its research and development pipeline. The firm has assigned an \"In-line\" rating to Shanghai Pharmaceuticals' (601607.SH) A-shares, with a target price of RMB 18.8.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0175","symbol_name":"白马股","start_time":0,"source_url":"","article_id":"1136361643","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1136361643","pubTimestamp":1778034376,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Morgan Stanley has issued a research report indicating that Shanghai Pharmaceuticals (02607) reported first-quarter revenue of RMB 75.3 billion, a year-on-year increase of 6.4%, and a net profit of...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"159982":"中证500","399300":"沪深300","601607":"上海医药","BK0175":"白马股","BK0196":"行业龙头","BK0012":"证金概念","BK0187":"一线龙头","BK0184":"上海国资改革","BK0028":"国家队","BK0099":"上海本地重组","BK0097":"医药电商","BK0020":"浦东新区","BK1197":"保健护理产品经销商","BK0183":"MSCI概念","BK0209":"零售","BK0188":"融资融券","02607":"上海医药"},"translate_title":"大摩：上海医药Q1业绩符合预期给予A股“一致”评级","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159982":1,"399300":1,"601607":1,"02607":1},"content_text":"Morgan Stanley has issued a research report indicating that Shanghai Pharmaceuticals (02607) reported first-quarter revenue of RMB 75.3 billion, a year-on-year increase of 6.4%, and a net profit of RMB 1.418 billion, also up 6.4% year-on-year. Both figures were in line with the firm's expectations. The report noted that Shanghai Pharmaceuticals is currently in discussions with multinational companies from the United States and the European Union regarding potential business development opportunities within its research and development pipeline. The firm has assigned an \"In-line\" rating to Shanghai Pharmaceuticals' (601607.SH) A-shares, with a target price of RMB 18.8.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1136361643","isCrawlerRequest":true}